The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) is a huge mover today! About 406,770 shares traded hands. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has risen 8.93% since April 26, 2016 and is uptrending. It has outperformed by 3.67% the S&P500.
The move comes after 9 months positive chart setup for the $5.53B company. It was reported on Nov, 29 by Barchart.com. We have $49.13 PT which if reached, will make NASDAQ:IONS worth $387.10 million more.
Analysts await Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report earnings on February, 23. They expect $-0.17 EPS, up 71.19% or $0.42 from last year’s $-0.59 per share. After $0.06 actual EPS reported by Ionis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -383.33% negative EPS growth.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Ratings Coverage
Out of 2 analysts covering Ionis Pharmaceuticals Inc (NASDAQ:IONS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Ionis Pharmaceuticals Inc has been the topic of 3 analyst reports since February 22, 2016 according to StockzIntelligence Inc. The firm earned “Market Perform” rating on Friday, May 27 by BMO Capital Markets. Needham maintained Ionis Pharmaceuticals Inc (NASDAQ:IONS) rating on Friday, May 27. Needham has “Buy” rating and $55 price target.
According to Zacks Investment Research, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.”
More notable recent Ionis Pharmaceuticals Inc (NASDAQ:IONS) news were published by: Fool.com which released: “3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017” on November 23, 2016, also Fool.com with their article: “Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today” published on November 07, 2016, Fool.com published: “3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition” on September 19, 2016. More interesting news about Ionis Pharmaceuticals Inc (NASDAQ:IONS) were released by: Fool.com and their article: “Better Buy: Ionis Pharmaceuticals, Inc. vs. Celgene” published on October 17, 2016 as well as Prnewswire.com‘s news article titled: “Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx” with publication date: November 15, 2016.
IONS Company Profile
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., incorporated on March 25, 1991, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Firm operates through two divisions: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the activities of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Firm is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. The Company’s Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.